No Data
Even with the start of the new fiscal year, active buying of leading stocks is likely to continue to be restrained.
This week, trading will primarily focus on short-term investments in bio-related stocks and IPOs as the new fiscal year begins. However, due to the implementation of additional tariffs by the US on April 2, along with strong concerns about the subsequent impact on the real economy, it is believed that active buying cannot be expected given the prevailing uncertainty. The Emerging Markets, centered on domestic demand, seem to be relatively stable compared to the Main Board market, but there is no feeling that the main indices in the Growth market will rise significantly. The Growth Market 250 Index has narrowed its gains.
CellSeed: Extraordinary Report
CellSeed: Confirmation
CellSeed: Financial Report - 24th Term (2024/01/01 - 2024/12/31)
Aftermarket [Stocks that moved and stocks that were traded]
*Grimmus <3150> 2417 +109 changed its dividend policy and upwardly revised the Financial Estimates for dividends for the fiscal year ending March 2025. * Tsubakimoto Industrial <6309> 4265 +1451 will split its stock by 3 shares. An upward revision of the dividends and a relaxation of the conditions for shareholder benefits were also announced. * Toho <9602> 7419 +141 has revised its dividend forecast upward for the fiscal year ending February 2025. The upside remains heavy. * Book Off Group Holdings <9278> 1492 +43 announced a Share Buyback of up to 12.14% of the issued shares and a purchase委託. Today is the 11th.
Stocks with a limit-up or limit-down in the afternoon session.
■Limit up <1787> Nakabo Tech <3985> Temona <4882> Perseus Proteomics <4896> Kei Pharma <7681> Leoclan <7776> Cellseed ■Limit down *Includes temporary limit up and down (indicative prices).